News
06-03-2009, 04:10 AM
CuraGen Corporation (Nasdaq: CRGN) reported three data presentations from its ongoing clinical trials of CR011-vcMMAE, an antibody-drug conjugate that targets GPNMB, in patients with advanced breast cancer and melanoma at the 2009 Annual Meeting of the American Society of Clinical Oncology (ASCO) in Orlando, Florida.
More... (http://www.medicalnewstoday.com/articles/152329.php)
More... (http://www.medicalnewstoday.com/articles/152329.php)